Sulfacetamide and Prednisolone
(sul fa SEE ta mide & pred NIS oh lone)
- Prednisolone and Sulfacetamide
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Blephamide: Sulfacetamide sodium 10% and prednisolone acetate 0.2% (3.5 g)
Solution, ophthalmic [drops]: Sulfacetamide sodium 10% and prednisolone sodium phosphate 0.25% (5 mL, 10 mL)
Suspension, ophthalmic [drops]:
Blephamide: Sulfacetamide sodium 10% and prednisolone acetate 0.2% (5 mL, 10 mL) [contains benzalkonium chloride]
Brand Names: U.S.
- Antibiotic/Corticosteroid, Ophthalmic
Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA; decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system
Use: Labeled Indications
Inflammatory ocular conditions: Treatment of steroid-responsive inflammatory ocular conditions in which a corticosteroid is indicated and where infection is present or there is a risk of infection; chronic anterior uveitis; corneal injury from chemical, radiation or thermal burns; penetration of foreign bodies.
Hypersensitivity to sulfacetamide, prednisolone, other sulfonamides or corticosteroids, or any component of the formulation; active viral infections (including herpes simplex keratitis, vaccinia, varicella) of the cornea or conjunctiva, fungal infection of ocular structures, or mycobacterial ocular infections
Inflammatory ocular conditions: Ophthalmic:
Ointment: Apply ~1/2 inch ribbon to lower conjunctival sac 3 to 4 times/day and 1 to 2 times at night
Solution: Instill 2 drops every 4 hours
Suspension: Instill 2 drops every 4 hours during the day and at bedtime
Refer to adult dosing.
Inflammatory ocular conditions: Children ≥6 years and Adolescents: Ophthalmic: Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
For topical ophthalmic use only; to avoid contamination, do not touch container tip to eyelids or other surfaces when placing drops or ointment in eyes. Do not apply with silver preparations. Discontinue if symptoms do not improve after 2 days. No more than 20 mL or 8 g should be prescribed without proper re-evaluation of the patient.
Ointment: Apply into pocket between eyeball and lower lid; patient should look downward before closing eye.
Solution/Suspension: Tilt head back, instill into the conjunctival sac and close eye(s). Apply light finger pressure on lacrimal sac for 1 minute following instillation. Shake the suspension well before using.
Ointment: Store at 15°C to 25˚C (59°F to 77°F).
Solution, suspension: Do not freeze; protect from light. May darken on prolonged standing or exposure to heat and light. Do not use if darkened; yellowing does not affect activity.
Solution: Store at 15°C to 25˚C (59°F to 77°F).
Suspension: Store at 8°C to 24˚C (46°F to 75°F) in upright position.
Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. Monitor therapy
NSAID (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Monitor therapy
Frequency not defined. Also see individual agents.
Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis, wound healing delayed
Hematologic: Agranulocytosis, aplastic anemia
Hepatic: Hepatic necrosis (fulminant)
Ocular: Accommodation loss, anterior uveitis (acute), intraocular pressure elevation, glaucoma, globe perforation, mydriasis, optic nerve damage (infrequent), posterior subcapsular cataract formation, ptosis
Miscellaneous: Allergic reactions, hypercorticoidism (systemic; rare), secondary infections (bacterial, fungal)
Concerns related to adverse effects:
• Blood dyscrasias: Severe reactions including agranulocytosis, aplastic anemia and other blood dyscrasias have occurred with sulfonamides (regardless of route). Discontinue at the first sign of serious reaction.
• Dermatologic reactions: Severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred with sulfonamides (regardless of route). Discontinue at first sign of rash.
• Hepatic necrosis: Fatalities associated with fulminant hepatic necrosis have occurred with sulfonamides (regardless of route). Discontinue at first sign of serious reaction.
• Hypersensitivity reactions: Rarely, systemic hypersensitivity reactions may occur.
• Infection: Steroids may mask infection or enhance existing ocular infection; prolonged use may result in secondary infections due to immunosuppression. Corticosteroids should not be used to treat ocular herpes simplex. Fungal infection should be suspected in any patient with persistent corneal ulceration who has received corticosteroids.
• Ocular effects: Prolonged use of steroids may result in glaucoma and injury to the optic nerve. Visual defects in acuity and field of vision and posterior subcapsular cataract formation may occur. Use with caution in presence of glaucoma (steroids increase intraocular pressure). Perforation may occur with topical steroids in diseases which thin the cornea or sclera. Steroid use may delay healing after cataract surgery. Intraocular pressure should be monitored if this product is used >10 days.
• Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.
• Dry eye: Use with caution in patients with severe dry eye.
• Contact lens wearers: Products may contain benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration.
Dosage form specific issues:
• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer’s labeling.
• Administration: For ophthalmic use only. Not for injection into the eye. Do not use concurrently with silver preparations.
• Appropriate use: Re-evaluate if signs and symptoms do not improve after 2 days. Use of >20 mL (solution/suspension) or 8 g (ointment) should only be done following proper re-examination of the patient (eg, slit-lamp biomicroscopy, fluorescein staining).
• Discontinuation of therapy: In chronic conditions, withdraw therapy with gradual tapering of dose.
• P-aminobenzoic acid: May be present in purulent exudates and may reduce the effectiveness of sulfonamides.
Signs and symptoms of improvement after 2 days of therapy; signs and symptoms of secondary infection; intraocular pressure in patients with glaucoma or with prolonged use (≥10 days); periodic exam of lens with prolonged use
Pregnancy Risk Factor
Animal reproduction studies have not been conducted with this combination. See individual agents.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Have patient report immediately to prescriber signs of a severe sulfonamide reaction (rash; red, swollen, blistered, or peeling skin; red or irritated eyes; sores in your mouth, throat, nose, or eyes; fever, chills, or sore throat; cough that is new or worse; loss of strength and energy; any bruising or bleeding; or signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes), vision changes, eye pain, or severe eye irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.